Second-generation immunomodulatory drugs in leptomeningeal myeloma

Jan-Paul Bohna Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria; Correspondence[email protected]
View further author information

Wolfgang Willenbachera Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria; ;b Oncotyrol, Center for Personalized Cancer Medicine, Innsbruck, Austria; View further author information

Ines Peschelc Central Institute for Medical and Chemical Laboratory Diagnostics, Medical University Innsbruck, Innsbruck, Austria; View further author information

Herbert Oberacherd Institute of Legal Medicine and Core Facility Metabolomics, Medical University of Innsbruck, Innsbruck, AustriaView further author information

Michael Steurera Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria; View further author information

References

Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002;117:103–108.
PubMed Web of Science ®Google Scholar
Chen CI, Masih-Khan E, Jiang H, et al. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol. 2013;162:483–488.
PubMed Web of Science ®Google Scholar
Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
PubMed Web of Science ®Google Scholar
Anwer S, Collings F, Trace K, et al. Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma. Br J Haematol. 2013;162:281–282.
PubMed Web of Science ®Google Scholar
Mussetti A, Dalto S, Montefusco V. Effective treatment of pomalidomide in central nervous system myelomatosis. Leuk Lymph. 2013;54:864–866.
PubMed Web of Science ®Google Scholar
Jurczyszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016;91:575–580.
PubMed Web of Science ®Google Scholar
Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymph. 2013;54:683–687.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Second-generation immunomodulatory drugs in leptomeningeal myeloma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Second-generation immunomodulatory drugs in leptomeningeal myeloma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date